Posted by Michael Wonder on 29 Jul 2025
FDA approves Apellis’ Empaveli (pegcetacoplan) as the first C3G and primary IC-MPGN treatment for patients 12 and older
28 July 2025 - Broad label includes adults and adolescents with C3G or primary IC-MPGN, and post-transplant C3G disease recurrence.
Apellis Pharmaceuticals today announced that the US FDA has approved Empaveli (pegcetacoplan) as the first treatment for C3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis in patients 12 years of age and older, to reduce proteinuria.
